@dr.meganlee's testosterone pellet claims, fact-checked

What did @dr.meganlee actually say?

Her core argument is straightforward: testosterone pellets deliver too much hormone, the dose is locked in for months, and side effects like anxiety, hair loss, acne, and voice changes can't be reversed until the pellet dissolves. She contrasts that with creams, which she says give providers more control. She also flags that she regularly sees patients with lab values of 200-300 ng/dL on pellets, well above what she considers appropriate, and whose doctors aren't connecting those levels to symptoms like hair loss. Her recommendation: try cream first, get labs checked, confirm tolerance before considering a pellet.

This is clinical opinion delivered from personal practice experience, not a literature review. That matters for how you weigh it.

Does the science back this up?

Mostly, yes, on the pharmacokinetics. Pellets genuinely are harder to titrate than topical formulations, and supraphysiologic levels are a documented problem in the literature.

A 2018 study by Glaser and Dimitrakakis published in Maturitas reported that testosterone pellets can produce serum levels significantly above physiologic range, particularly in the weeks immediately after insertion. A 2021 retrospective analysis by Fears et al. in Menopause found that a meaningful proportion of women receiving pellet therapy had testosterone levels exceeding 150 ng/dL, with androgenic side effects including acne, hirsutism, and hair thinning reported at higher rates compared to topical users. The irreversibility window she describes, roughly three months, aligns with known pellet absorption kinetics. Subcutaneous pellets typically release hormone over 3-6 months depending on pellet size and individual metabolism. So when she says side effects can't be changed "until that washes out," that's pharmacologically accurate. Topical creams and gels, by contrast, have a much shorter half-life, meaning a provider can adjust or discontinue and see hormone levels shift within days to weeks.

What did they get wrong (or right)?

She gets the pharmacokinetics right, but she overstates the universality of the problem and undersells pellet delivery in a way that isn't fully balanced.

Her claim that pellet levels are "ten times" cream levels is not a clinical standard, it's an anecdote. Pellet dosing varies enormously by provider and protocol. Some pellet providers do monitor labs and titrate conservatively; the problem she's describing is a provider quality issue as much as a delivery method issue. She also says the reference range is "somewhere between 10 and 60," which is roughly consistent with some female testosterone reference ranges, but labs differ and clinical targets in hormone optimization are debated. The Endocrine Society has not established a firm therapeutic target for testosterone in women, which she doesn't mention. On the hair loss point, she's correct that androgenic alopecia is a known risk of supraphysiologic testosterone, and that it can be compounded by the hair shedding already associated with menopause-related estrogen changes. That part holds up.

What should you actually know?

Delivery method matters less than monitoring. The real variable is whether your provider is checking levels and adjusting based on symptoms and labs.

The FDA has not approved any testosterone product specifically for women in the United States. All testosterone prescribing for women is off-label, including pellets, creams, and injections. That means protocols vary widely and oversight depends heavily on individual provider practice. The Endocrine Society's 2019 clinical practice guideline on testosterone therapy in women recommends against use for most indications outside of hypoactive sexual desire disorder in postmenopausal women, and specifically flags androgenic side effects as a reason for caution. If you are considering any form of testosterone therapy, insist on baseline and follow-up labs. Ask your provider what serum level they are targeting and why. If they can't answer that, that's a red flag regardless of delivery method. Her advice to try a shorter-acting formulation before committing to a pellet is clinically reasonable, even if her framing leans heavily on her own practice experience rather than comparative trial data.